Denali Therapeutics (Denali Therapeutics) Total Assets

: $1,153.9 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

Denali Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $1,153.9 Mil.

During the past 12 months, Denali Therapeutics's average Total Assets Growth Rate was -3.70% per year. During the past 3 years, the average Total Assets Growth Rate was -3.90% per year. During the past 5 years, the average Total Assets Growth Rate was -4.10% per year.

During the past 9 years, Denali Therapeutics's highest 3-Year average Total Assets Growth Rate was 221.60%. The lowest was -3.90%. And the median was 16.40%.

Total Assets is connected with ROA %. Denali Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -39.98%. Total Assets is also linked to Revenue through Asset Turnover. Denali Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Denali Therapeutics Total Assets Historical Data

The historical data trend for Denali Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

553.23

1,604.28

1,404.16

1,460.24

1,153.92

Denali Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets																1,460.24	1,409.34	1,305.73	1,236.78	1,153.92

Denali Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Denali Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	1030.954	+	122.963
	=	1,153.9

Denali Therapeutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	1030.954	+	122.963
	=	1,153.9

Denali Therapeutics (NAS:DNLI) Total Assets Explanation

Total Assets is connected with ROA %.

Denali Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-477.892	/	( (1236.777	+	1153.917)	/ 2 )
	=	-477.892	/	1195.347
	=	-39.98 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Denali Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (1236.777	+	1153.917)	/ 2 )
=	0	/	1195.347
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Denali Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Denali Therapeutics (Denali Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (NAS:DNLI) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

4DN:Germany

Address

161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.denalitherapeutics.com

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Executives

Vicki L Sato	director	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Carole Ho	officer: Chief Medical Officer	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Ryan J. Watts	director, officer: President and CEO	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Steve E. Krognes	officer: CFO and Treasurer	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Alexander O. Schuth	officer: COO and Secretary	C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Marc Tessier-lavigne	director	1 DNA WAY, SOUTH SAN FRANCISCO CA 94080
Erik Harris	director	60 LEVERONI COURT, NOVATO CA 94949
Douglas K Bratton	10 percent owner	201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102
Nancy Thornberry	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
David P Schenkein	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Arch Venture Partners Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Viii, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631